Extracontraceptive benefits of EE/DRSP (YAZ) in 24+4 day regimen;Benefici extracontraccettivi di EE/DRSP nel regime 24+4 (YAZ)

Minerva Ginecologica

Volumn 62, Issue 3, 2010, Pages 261-266

  Bruni Bresciani, V ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Contraception; Contraceptives, oral, hormonal; Premenstrual syndrome

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; HORMONE; ORAL CONTRACEPTIVE AGENT;

ACNE; BREAST TENDERNESS; DRUG DOSE REGIMEN; DRUG EFFECT; HEADACHE; HIRSUTISM; HUMAN; MOOD CHANGE; OUTCOME ASSESSMENT; OVULATION; PELVIS PAIN SYNDROME; PREMENSTRUAL SYNDROME; REVIEW; WITHDRAWAL SYNDROME;

ACNE VULGARIS; ANDROSTENES; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HIRSUTISM; HUMANS; PREMENSTRUAL SYNDROME; REPRODUCTIVE CONTROL AGENTS;

EID: 77957721640     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Arisi E. Consumo e compliance dei contraccettivi ormonali. Riv It Ost Gin 2004;2:63-8.
2. American College of obstetricians and Gynecologists. Noncontraceptive uses of hormonal contraceptives. Practice Bulletin 2010;115:1.
3. Short M. User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 mcg (Yasminelle) in clinical practice: a multi-country, questionnaire-based study. Clin Drug Investig 2009;29:153-9.
4. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-6.
5. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78:16-25.
6. Sulak PJ. Ovulation suppression of premenstrual symptoms using oral contraceptives The Am J Managed Care 2005;Suppl 11,16:492-7.
7. Bachmann G, Kopacz S. Drospirenone/ethynil estradiol 3 mg/20 Ìg (24/4 regimen): hormonal contraceptive choices-use of a fourth-generation progestin. Patient Prefer Adherence 2009;3:259-64.
8. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004;217:255-61
9. Elger W, Beier S. Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891-905.
10. Lopez LM, Kaptein AA. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane database syst review 2009;15:2.
11. Breech L, Braverman K. Safety, efficacy, actions, and patients acceptability of drospirenone/ethynil estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. Int J of Women's Health 2009;1:85-95.
12. Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res 2009;9:157-70.
13. Hernádi L, Marr J, Trummer D, De Leo V, Petraglia F. Efficacy and safety of a low dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception 2009;80:18-24.
14. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008;53(9 Suppl):729-41.
15. Sangthawan M, Taneepanichskul S. Comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 Ìg on premenstrual symptoms. Contraception 2005;71:1-7. (Pubitemid 41583140)
16. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics Gynecol 2005;106;3:492-501. (Pubitemid 41208780)
17. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-21.
18. Genazzani AR, Pluchino N, Begliuomini S, Pieri M, Centofanti M, Freschi L et al. Drospirenone increases central and peripheral beta.endorphin in ovariectomized female rats. Menopause 2007;24:63-73. (Pubitemid 46072007)
19. Maloney MJ, Dietze P Jr, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 Ìg EE in the treatment of acne vulgaris: lesion counts, investigator rating and subject self-assessment J Drugs Dermatol 2009;8,9:838-44.
20. Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008;77:249-56.
21. Magin P, Adams J, Heading G, Pond D, Smith W. Psychological sequelae of acne vulgaris. Results of a qualitative study. Can Fam Physician 2006;52:979-85.
22. Thomas DR. Psychosocial effects of acne. J Cutan Med Surg 2004;Suppl 4:3-5.
23. Batukan C, Muderris II, Ozcelik B, Ozturk. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecological Endocr 2007;23:38-44.
24. Bitzer J, Paoletti AM. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin Drug Investig 2009;29:73-8.
25. Caprio M, Fève B, Claes A, Viengchareun S, Lombès M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007;21:2185-94. (Pubitemid 47026453)
26. Emanuel EJ, Emanuel LL. The physician-patient relationship. JAMA 1992;22-29;267:2221-6
27. Fu H, Darroch JE, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plan Perspect 1999;31:56-63.
28. Haynes RB, Taylor DW, Sackett DL. Compliance in health care. Baltimore: J Hopkins University Press; 1979.
29. Majani G. Compliance, adesione, aderenza. I punti critici della relazione terapeutica. Milano: Mc Graw-Hill; 2001.
30. Otto C, Fuchs I, Altmann H, Kiewer M, Walter A, Prelle K et al. Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate. Endocrinology 2008;149:3952-9.